Effects of a Thermosensitive In Situ Gel Containing Mometasone Furoate on a Rat Allergic Rhinitis Model

Abstract

Background

Mometasone furoate, one of the second generation intranasal corticosteroids, is currently used in suspension form due to its poor solubility. However, this is not favorable for nasal application because of the rapid elimination of the instilled drug from the nasal cavity by mucociliary clearance and delayed onset of action due to the slow dissolution of drug in suspension.

Objective

The aim of this study was to determine the antiallergic effects of mucoadhesive thermosensitive in situ gel containing mometasone furoate that we developed previously to prolong the contact between the drug and nasal mucosa and to prevent drainage of the formulation in an ovalbumin-induced rat model of allergic rhinitis.

Methods

An experimental allergic rhinitis model was developed in female Wistar albino rats by intraperitoneal injection of ovalbumin every 2 days for 14 days followed by its repeated intranasal instillation for 7 consecutive days. Intranasal instillation of ovalbumin was continued every other day for 14 days. Mometasone furoate in situ gel (5 μg/10 µl), mometasone furoate suspension (5 μg/10 µl), and physiological saline (10 µl) were administered into the bilateral nasal cavities from day 22 to day 35. Antiallergic effects were evaluated through histopathological evaluation, analysis of ovalbumin-specific serum immunoglobulin E, and a symptom score.

Results

Mometasone furoate in situ gel significantly decreased the nasal symptoms and ovalbumin-specific serum immunoglobulin E level as compared with mometasone furoate suspension and physiological saline. Additionally, inflammatory histological symptoms such as mucosal edema, vascular dilatation, eosinophil infiltration, and loss of cilia within the nasal mucosa of allergic rhinitis model rats were remarkably improved with the treatment of mometasone furoate in situ gel.

Conclusion

These results suggest that mometasone furoate in situ gel has a better therapeutic potential for the treatment of allergic rhinitis compared to mometasone furoate suspension.

Keywords

thermosensitive in situ gel mucoadhesive allergic rhinitis mometasone furoate intranasal corticosteroids suspension rat model ovalbumin immunoglobulin histopathological evaluation

Get full access to this article

View all access options for this article.

References

Altuntaş

Yener

Formulation and evaluation of thermoreversible in situ nasal gels containing mometasone furoate for allergic rhinitis. AAPS PharmSciTech. 2017; 18:2673–2682.

Ciprandi

Cirillo

Vizzaccaro

et al . Seasonal and perennial allergic rhinitis: is this classification adherent to real life? Allergy. 2005; 60:882–887.

Cantone

Iengo

Effect of sodium hyaluronate added to topical corticosteroids in chronic rhinosinusitis with nasal polyposis.

Am J Rhinol Allergy. 2016; 30:340–343.

Illum

Jørgensen

Bisgaard

et al . Bioadhesive microspheres as a potential nasal drug delivery system. Int J Pharm. 1987; 39:189–199.

Gizurarson

The relevance of nasal physiology to the design of drug absorption studies.

Adv Drug Deliv Rev. 1993; 11:329–347.

Ruel-Gariepy

Leroux

J-C.

In situ-forming hydrogels—review of temperature-sensitive systems.

Eur J Pharm Biopharm. 2004; 58:409–426.

Wen

W-D

Yuan

Wang

J-L

et al . Botulinum toxin therapy in the ovalbumin-sensitized rat. Neuroimmunomodulation. 2007; 14:78–83.

Tsumuro

Ogawa

Minami

et al . Effects of mometasone furoate on a rat allergic rhinitis model. Eur J Pharmacol. 2005; 524:155–158.

Yasar

Savranlar

Karaman

et al . Effects of propolis in an experimental rat model of allergic rhinitis. Am J Otolaryngol. 2016; 37:287–293.

10.

Shimizu

Hirano

Majima

et al . A mechanism of antigen-induced mucus production in nasal epithelium of sensitized rats: a comparison with lipopolysaccharide-induced mucus production. Am J Respir Crit Care Med. 2000; 161:1648–1654.

11.

Berlucchi

Pedruzzi

Intranasal mometasone furoate for treatment of allergic rhinitis.

Clin Med Insights Ther. 2010; 2:761.

12.

Dykewicz

Fineman

Skoner

et al . Diagnosis and management of rhinitis: complete guidelines of the joint task force on practice parameters in allergy, asthma and immunology. Ann Allergy Asthma Immunol. 1998; 81:478–518.

13.

Bégin

Nadeau

KC.

Epigenetic regulation of asthma and allergic disease.

Allergy Asthma Clin Immunol. 2014; 10:27.

14.

Lundblad

Torkjel

Dominika

DL.

Mometasone furoate nasal spray in the treatment of perennial non-allergic rhinitis: a nordic, multicenter, randomized, double-blind, placebo-controlled study.

Acta Otolaryngol. 2001; 121:505–509.

15.

Dibildox

Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: results of recent clinical trials.

J Allergy Clin Immunol. 2001; 108:S54–S58.

16.

Crim

Pierre

Daley-Yates

PT.

A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate.

Clin Therapeut. 2001; 23:1339–1354.

17.

Brannan

Seiberling

Cutler

et al . Lack of systemic activity with intranasal mometasone furoate. J Allergy Clin Immunol. 1996; 97:198.

18.

Shii

Nakagawa

Yoshimi

et al . Inhibitory effects of cyclosporine a eye drops on symptoms in late phase and delayed-type reactions in allergic conjunctivitis models. Biol Pharmaceut Bull. 2010; 33:1314–1318.

19.

Saito

Matsumoto

Denburg

et al . Pathogenesis of murine experimental allergic rhinitis: a study of local and systemic consequences of IL-5 deficiency. J Immunol. 2002; 168:3017–3023.

20.

Melgert

Postma

Kuipers

et al . Female mice are more susceptible to the development of allergic airway inflammation than male mice. Clin Exp Allergy. 2005; 35:1496–1503.

21.

Assanasen

Baroody

Rouadi

et al . Ipratropium bromide increases the ability of the nose to warm and humidify air. Am J Respir Crit Care Med. 2000; 162:1031–1037.

22.

Brozmanova

Calkovský

Plevkova

et al . Early and late allergic phase related cough response in sensitized guinea pigs with experimental allergic rhinitis. Physiol Res. 2006; 55:577.

23.

Senturk

Yildirim

Dogan

et al.

Assessment of the effectiveness of cyclosporine nasal spray in an animal model of allergic rhinitis. Eur Arch Otorhinolaryngol. 2018; 275:117–124.

24.

Aswar

Kandhare

Mohan

et al . Anti‐allergic effect of intranasal administration of type‐A procyanidin polyphenols based standardized extract of cinnamon bark in ovalbumin sensitized BALB/c mice. Phytother Res. 2015; 29:423–433.

25.

Y-Y

Liu

Dai

L-B

et al . Effect of Tong Qiao drops on the expression of eotaxin, IL-13 in the nasal mucosa of rats with allergic rhinitis. J Chin Med Assoc. 2012; 75:524–529.

26.

Sugimoto

Ishizawa

Saitou

et al . Effect of mometasone furoate by topical application on allergic rhinitis model in rats. Pharmacology. 2000; 61:91–95.

27.

Cao

Zhang

Jiang

XG.

Preparation of ion‐activated in situ gel systems of scopolamine hydrobromide and evaluation of its antimotion sickness efficacy.

Acta Pharmacol Sin. 2007; 28:584–590.

28.

Yman

Standardization of in vitro methods.

Allergy. 2001; 56:70–74.

29.

Bahekar

Shah

Ayer

et al . Validation of guinea pig model of allergic rhinitis by oral and topical drugs. Int Immunopharmacol. 2008; 8:1540–1551.

30.

Guibas

Spandou

Meditskou

et al . N‐acetylcysteine exerts therapeutic action in a rat model of allergic rhinitis. Int Forum Allergy Rhinol. 2013; 3:543–549.

31.

Nakaya

Dohi

Okunishi

et al . Prolonged allergen challenge in murine nasal allergic rhinitis: nasal airway remodeling and adaptation of nasal airway responsiveness. Laryngoscope. 2007; 117:881–885.

32.

S-h

Zhang

H-y

Zeng

X-n

et al . Mast cells and basophils are essential for allergies: mechanisms of allergic inflammation and a proposed procedure for diagnosis. Acta Pharmacol Sin. 2013; 34:1270–1283.